top of page

9/20 - 9/27 North America Healthcare Market Weekly Report

<Weekly Report>





<References>


[1]Second dose of J&J's coronavirus vaccine increases protection, company says | Healthcare Dive

[2] https://news.google.com/covid19/map?hl=en-US&mid=%2Fm%2F02j71&gl=US&ceid=US%3Aen

https://www.worldometers.info/coronavirus/?utm_campaign=instagramcoach1?

[3]https://covid.cdc.gov/covid-data-tracker/#vaccinations

[4] US buying 500M more doses of Pfizer coronavirus vaccine for donation to world | BioPharma Dive

[5]FDA green lights booster dose of Pfizer vaccine for older, more vulnerable Americans | Healthcare Dive

[6] These Health Care Workers Would Rather Get Fired Than Get Vaccinated - The New York Times (nytimes.com)

[7]HCA to acquire 5 Utah hospitals from Steward Health Care | Healthcare Dive

[8] Seagen, Genmab win speedy FDA approval for cervical cancer drug | BioPharma Dive

[9]https://www.fiercebiotech.com/medtech/boston-scientific-offers-up-336m-to-devour-devoro-medical-and-its-blood-clot-removal-tech

[10] AHA-backed study predicts hospitals could lose $54B in profit this year | Healthcare Dive

[11] Incyte eczema drug wins FDA OK, but with safety warning | BioPharma Dive

[12]6 drug companies could face steep fines for violating 340B law | Healthcare Dive

[13] Centene, Humana sue Merck for 'monopolistic scheme' to delay generics of blockbuster cholesterol drug | Healthcare Dive

[14]Biden-Harris Administration Awards $15 Million to 20 States for Mobile Crisis Intervention | HHS.gov

[15] OIG flags potential $5B overpaid to Medicare Advantage plans | Healthcare Dive

[16]CMS official says Medicaid must cover Aduhelm as industry awaits national coverage decision | FierceHealthcare

[17] Regeneron and Roche's COVID drug wins WHO backing, but agency calls for lower prices and better access | FiercePharma

[18]CDC recommends Pfizer booster shots for many, overruling advisers on broad use | Healthcare Dive

[19]As Budget Bill Talks Intensify, Here Are the Five Biggest Issues Dividing Democrats - WSJ

1 view0 comments
bottom of page